文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

内皮功能障碍与糖尿病心肌病。

Endothelial Dysfunction and Diabetic Cardiomyopathy.

机构信息

Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Emergency, Tongji Hospital, Tongji Medical College, Science and Technology, Huazhong University, Wuhan, China.

出版信息

Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.


DOI:10.3389/fendo.2022.851941
PMID:35464057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9021409/
Abstract

The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.

摘要

心血管并发症是导致糖尿病相关发病率和死亡率的主要原因,占 1 型糖尿病 (DM) 患者死亡的 44%,2 型 DM 患者死亡的 52%。糖尿病通过两种主要机制引起心血管功能障碍:缺血性和非缺血性。非缺血性损伤在糖尿病患者中很常见,但通常未被认识到,也是合并缺血性心脏病的糖尿病个体心力衰竭的致病因素。糖尿病心肌病 (DCM) 是指在没有冠状动脉疾病、高血压、瓣膜或先天性心脏病的糖尿病患者中,心肌结构和功能异常的心脏病,理论上仅由非缺血性损伤引起。目前针对 DCM 的治疗策略主要针对血糖升高,但对心脏功能的影响令人失望。越来越多的证据表明内皮功能障碍在 DCM 的发生和发展中起关键作用。高血糖、高胰岛素血症和胰岛素抵抗导致内皮功能受损,包括屏障功能障碍、一氧化氮 (NO) 活性受损、活性氧 (ROS) 产生过多、氧化应激和炎症失调。反过来,内皮功能障碍会促进心肌代谢受损、细胞内 Ca 处理异常、内质网 (ER) 应激、线粒体缺陷、晚期糖基化终产物的积累和细胞外基质 (ECM) 沉积,导致心脏僵硬度增加、纤维化和重塑,最终导致心脏舒张功能障碍、收缩功能障碍和心力衰竭。虽然内皮功能障碍与 DCM 中观察到的心脏功能障碍和心力衰竭密切相关,但恢复内皮功能的临床策略仍存在缺失。本综述总结了与内皮功能障碍对心肌紊乱及心脏功能的影响相关的最新发现,为 DCM 发病机制和病理生理学提供了力学见解,并强调了潜在的治疗靶点。

相似文献

[1]
Endothelial Dysfunction and Diabetic Cardiomyopathy.

Front Endocrinol (Lausanne). 2022

[2]
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.

Int J Mol Sci. 2019-7-2

[3]
The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools.

Int J Mol Sci. 2023-5-11

[4]
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Circ Res. 2018-2-16

[5]
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.

Heart Fail Rev. 2023-5

[6]
Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.

Endocr Metab Immune Disord Drug Targets. 2021

[7]
Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy.

Acta Pharmacol Sin. 2018-6-4

[8]
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.

Int J Mol Sci. 2022-3-25

[9]
Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Heart Fail Rev. 2012-5

[10]
The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas.

Oxid Med Cell Longev. 2017-7-11

引用本文的文献

[1]
Predicting diabetic cardiomyopathy in type 2 diabetes: development and validation of a nomogram based on clinical and echocardiographic parameters.

Front Endocrinol (Lausanne). 2025-8-8

[2]
Mechanistic Insights Into Qidan Yixin Decoction for Diabetic Cardiomyopathy via Macrophage Polarization.

J Diabetes Res. 2025-7-31

[3]
Multifunctional gold nanoclusters as next-generation theranostic platforms for disease management.

Int J Pharm X. 2025-7-21

[4]
Therapeutic potential of traditional Chinese medicine in diabetic cardiomyopathy: a review.

Front Endocrinol (Lausanne). 2025-7-23

[5]
Mechanisms and therapeutics of insulin signaling transduction genes in diabetic cardiomyopathy: a comprehensive updated review.

Front Endocrinol (Lausanne). 2025-7-17

[6]
From Type 2 Diabetes Mellitus To Diabetic Cardiomyopathy - A Systematic Review On The Role Of MicroRNA.

Curr Diab Rep. 2025-7-15

[7]
Interaction between mitochondrial oxidative stress and myocardial fibrosis in the context of diabetes.

Front Endocrinol (Lausanne). 2025-6-5

[8]
Impact of elevated glucose levels on cardiac function in STEMI patients: glucose delta as a prognostic biomarker.

Diabetol Metab Syndr. 2025-6-10

[9]
Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15.

Int J Mol Sci. 2025-5-11

[10]
Molecular Mechanisms of Type 2 Diabetes-Related Heart Disease and Therapeutic Insights.

Int J Mol Sci. 2025-5-9

本文引用的文献

[1]
IL-6/STAT3 Signaling Promotes Cardiac Dysfunction by Upregulating FUNDC1-Dependent Mitochondria-Associated Endoplasmic Reticulum Membranes Formation in Sepsis Mice.

Front Cardiovasc Med. 2022-1-18

[2]
Endothelial Progenitor Cell-Derived Extracellular Vesicles: Potential Therapeutic Application in Tissue Repair and Regeneration.

Int J Mol Sci. 2021-6-15

[3]
EndMT Regulation by Small RNAs in Diabetes-Associated Fibrotic Conditions: Potential Link With Oxidative Stress.

Front Cell Dev Biol. 2021-5-19

[4]
Reactive Oxygen Species-Induced TRPM2-Mediated Ca Signalling in Endothelial Cells.

Antioxidants (Basel). 2021-5-3

[5]
Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes.

Cardiovasc Res. 2022-1-7

[6]
Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction.

J Am Coll Cardiol. 2020-12-15

[7]
Stress-induced RNA-chromatin interactions promote endothelial dysfunction.

Nat Commun. 2020-10-15

[8]
Cells of the adult human heart.

Nature. 2020-12

[9]
Hyperinsulinemia promotes endothelial inflammation via increased expression and release of Angiopoietin-2.

Atherosclerosis. 2020-8

[10]
Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities.

Basic Res Cardiol. 2020-5-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索